New nanobody CAR t therapy targets tough leukemia
NCT ID NCT06880913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of CAR T-cell therapy that uses nanobodies to target two proteins (CD19 and CD22) on leukemia cells. It is for people aged 12 to 65 whose B-cell acute lymphoblastic leukemia has come back or not responded to other treatments. The goal is to see if this therapy can safely put the cancer into remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Deparment of Hematology, Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China